Article Text
Electronic pages
Correspondence
Difference between Enbrel and Benepali treatment groups in ‘hepatobiliary disorders’
Statistics from Altmetric.com
We read with interest the study from Emery et al1 reporting the phase III trial comparing the biosimilar SB4 with originator etanercept, as well as the summary for the public that appeared in the European Public Assessment Report (EPAR)2 issued by European Medicines Agency on 28 January 2016. In our reading of the documents, we were …